Unraveling NEAT1's complex role in lung cancer biology: a comprehensive review.

PubMed, Journal Year: 2024, Volume and Issue: 23, P. 34 - 52

Published: Jan. 1, 2024

This review delves into the pivotal role of long non-coding RNA NEAT1 in cancer biology, particularly lung (LC). It emphasizes NEAT1's unique subcellular localization and active involvement gene regulation chromatin remodeling. The highlights impact on LC development progression, including cell processes such as proliferation, migration, invasion, resistance to therapy, positioning it a potential diagnostic marker therapeutic target. complex web regulatory interactions with proteins microRNAs is explored, alongside challenges targeting therapeutically. concludes optimistically, suggesting future avenues for research personalized therapies, shedding light crucial LC. See also Graphical abstract(Fig. 1).

Language: Английский

---

Novel therapeutic approaches for non-small cell lung cancer: an updated view

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 29

Published: April 5, 2025

Non-small cell lung cancer (NSCLC) continues to be one of the leading causes cancer-related mortality globally. Most patients who undergo surgical procedures may encounter distant metastasis or local recurrence, necessitating supplementary treatments such as radiation therapy, chemotherapy, targeted therapy adjuvant alternatives. Recent advancements in molecular biology and immunotherapy have paved way for innovative therapeutic approaches that target specific genetic mutations promote immune response against tumor cells. This review explores emerging therapies, including therapies tyrosine kinase inhibitors (TKIs) actionable (e.g., EGFR, ALK, ROS1), well role checkpoint (ICIs) employ body's system combat cancer. Additionally, we discuss potential exosome promising nanotherapeutic options treatment NSCLC. study attempts provide a thorough overview changing landscape NSCLC its implications enhancing patient outcomes by presenting these techniques.

Language: Английский

---

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: March 16, 2024

Abstract The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development immune checkpoint inhibitors (ICI), but range clinical responses observed among patients poses significant challenges. To date, analyses tumor biopsies are only parameter used to guide prognosis ICI therapy. Tumor biopsies, however, often difficult obtain and tissue-based biomarkers limited intratumoral heterogeneity temporal variability. In response, there a growing emphasis on “liquid biopsy”‒ derived biomarkers, which offer minimally invasive means dynamically monitor status NSCLC either before and/or during course treatment. Here we review studies in multiple blood-based encompassing circulating soluble analytes, subsets, DNA, mutational burden, cells have shown promising associations with response These investigations unveiled compelling correlations between peripheral both therapy patient outcomes, include rates, progression-free survival, overall survival. There is need for rigorous validation standardization these assays broader application. Integration into comprehensive panels or algorithms also potential enhance predictive accuracy. Further research aimed at longitudinal monitoring crucial comprehend dynamics resistance mechanisms should be alongside methods that interrogate microenvironment decisions may inform novel therapeutic strategies. data reviewed here reinforce opportunity refine stratification, optimize treatments, improve outcomes not wider spectrum solid tumors undergoing immunotherapy.

Language: Английский

---

The potential role of circular RNAs -regulated PI3K signaling in non-small cell lung cancer: Molecular insights and clinical perspective

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 257, P. 155316 - 155316

Published: April 16, 2024

Language: Английский

---

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(14), P. 4189 - 4189

Published: July 18, 2024

The leading cause of cancer deaths worldwide is attributed to non-small cell lung (NSCLC), necessitating a continual focus on improving the diagnosis and treatment this disease. In review, latest breakthroughs emerging trends in managing NSCLC are highlighted. Major advancements diagnostic methods, including better imaging technologies utilization molecular biomarkers, discussed. These have greatly enhanced early detection personalized plans. Significant improvements patient outcomes been achieved by new targeted therapies immunotherapies, providing hope for individuals with advanced NSCLC. This review discusses persistent challenges accessing treatments their associated costs despite recent progress. Promising research into therapies, such as CAR-T therapy oncolytic viruses, which could further revolutionize treatment, also aims inform inspire continued efforts improve patients globally, offering comprehensive overview current state future possibilities.

Language: Английский

---

Natural Compounds for Preventing Age-Related Diseases and Cancers

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7530 - 7530

Published: July 9, 2024

Aging is a multifaceted process influenced by hereditary factors, lifestyle, and environmental elements. As time progresses, the human body experiences degenerative changes in major functions. The external internal signs of aging manifest various ways, including skin dryness, wrinkles, musculoskeletal disorders, cardiovascular diseases, diabetes, neurodegenerative cancer. Additionally, cancer, like aging, complex disease that arises from accumulation genetic epigenetic alterations. Circadian clock dysregulation has recently been identified as an important risk factor for cancer development. Natural compounds herbal medicines have gained significant attention their potential preventing age-related diseases inhibiting progression. These demonstrate antioxidant, anti-inflammatory, anti-proliferative, pro-apoptotic, anti-metastatic, anti-angiogenic effects well circadian regulation. This review explores cancers, specific natural targeting key features these conditions.

Language: Английский

---

Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review

MedComm, Journal Year: 2024, Volume and Issue: 5(12)

Published: Nov. 24, 2024

Abstract Lung cancer (LC) continues to pose the highest mortality and exhibits a common prevalence among all types of cancer. The genetic interaction between human eukaryotes microbial cells plays vital role in orchestrating every physiological activity host. dynamic crosstalk gut lung microbiomes gut–lung axis communication network has been widely accepted as promising factors influencing LC progression. advent 16s rDNA sequencing technique opened new horizons for elucidating microbiome its potential pathophysiological other infectious diseases using molecular approach. Numerous studies have reported direct involvement host tumorigenesis processes their impact on current treatment strategies such radiotherapy, chemotherapy, or immunotherapy. metabolomic cross‐interaction, microbiome‐dependent immune modulation, close association microbiota composition outcomes strongly suggest that designing microbiome‐based investigating molecules targeting holobiome could offer alternatives develop effective therapeutic principles treatment. This review aims highlight progression possibility manipulating altered ecology targets.

Language: Английский

---

Cutting-Edge Therapies for Lung Cancer

Cells, Journal Year: 2024, Volume and Issue: 13(5), P. 436 - 436

Published: March 1, 2024

Lung cancer remains a formidable global health challenge that necessitates inventive strategies to improve its therapeutic outcomes. The conventional treatments, including surgery, chemotherapy, and radiation, have demonstrated limitations in achieving sustained responses. Therefore, exploring novel approaches encompasses range of interventions show promise enhancing the outcomes for patients with advanced or refractory cases lung cancer. These groundbreaking can potentially overcome resistance offer personalized solutions. Despite rapid evolution emerging therapies, persistent challenges such as resistance, toxicity, patient selection underscore need continued development. Consequently, landscape therapy is transforming introduction precision medicine, immunotherapy, innovative modalities. Additionally, multifaceted approach involving combination therapies integrating targeted agents, immunotherapies, traditional cytotoxic treatments addresses heterogeneity while minimizing adverse effects. This review provides brief overview latest are reshaping treatment. As these progress through clinical trials integrated into standard care, potential more effective, targeted, comes focus, instilling renewed hope facing challenging diagnoses.

Language: Английский

---

Harnessing IL-27: challenges and potential in cancer immunotherapy

Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 11, 2025

IL-27 is structurally an immune-enhancing and pleiotropic two-chain cytokine associated with IL-12 IL-6 families. contains two subunits, namely IL-27p28 EBI3. A heterodimer receptor of IL-27, composed IL27Rα (WSX1) IL6ST (gp130) chains, mediates the function following activation STAT1 STAT3 signaling pathways. Specifically, identified as augmenting immune responses, including Th1 cell differentiation, TCd4 + proliferation, IFN-γ production help IL-12. According to several published studies, due pro-inflammatory or anti-inflammatory functions related biological context in various disorders diseases, has been considered a complex regulator system. Surprisingly, dual role same double-edged sword, also evidenced clinical models hematological solid tumors. Predominantly, Il-27 applies anti-tumor by inducing responses cytotoxic T lymphocyte (CTL) suppressing growth, angiogenesis, invasiveness, metastasis, survival tumor cells. On other hand, may play protumor cancers induce progression. The current update study aimed summarize different malignancies

Language: Английский

---

Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review

Cancers, Journal Year: 2024, Volume and Issue: 16(13), P. 2338 - 2338

Published: June 26, 2024

Non-small-cell lung cancer (NSCLC) comprises approximately 85% of all cases, often diagnosed at advanced stages, which diminishes the effective treatment options and survival rates. This systematic review assesses utility emerging biomarkers-circulating tumor DNA (ctDNA), microRNAs (miRNAs), blood mutational burden (bTMB)-enhanced by next-generation sequencing (NGS) to improve diagnostic accuracy, prognostic evaluation, strategies in NSCLC. Analyzing data from 37 studies involving 10,332 patients 2020 2024, highlights how biomarkers like ctDNA PD-L1 expression critically inform selection personalized therapies, particularly beneficial stages These are critical for assessments dynamically adapting plans, where high specific genetic mutations (e.g., ALK fusions, EGFR mutations) significantly guide use targeted therapies immunotherapies. The findings recommend integrating these into standardized clinical pathways maximize their potential enhancing precision, ultimately fostering significant advancements oncology improving patient outcomes quality life. substantiates predictive value emphasizes need ongoing innovation biomarker research.

Language: Английский

---